Navigation Links
QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Date:7/26/2010

S studies was considered acceptable for MAA submission in Europe with the addition of a Phase 3 study in bunionectomy patients comparing the adverse event profile of MoxDuo IR to equianalgesic doses of morphine and of oxycodone (total n=300). This study will include the proposed primary safety endpoints of the occurrence rate of moderate-severe nausea, emesis or dizziness, with an improvement for MoxDuo IR compared to morphine and oxycodone treatments being defined as a clinically relevant effect.

Assuming a positive outcome of this additional study and pending review of the MAA, such differences may be cited in the product package labelling in Europe and will further augment data for label claim submission with the FDA in the US.

QRxPharma successfully completed a pivotal Phase 3 "combination rule" study in April 2010 and announced that primary and secondary endpoints were achieved. In this study, MoxDuo IR 2 demonstrated both a statistically superior analgesic effect compared to morphine and oxycodone alone as well as a favourable side effect profile despite delivering twice the opioid dose of its individual components. These findings complement earlier clinical trials demonstrating that MoxDuo IR opens the therapeutic window by providing significant acute pain relief while reducing side effects.

About Scientific Advice:

The Scientific Advice process provides QRxPharma a forum to discuss the adequacy of its MoxDuo IR development plan as well as the results obtained to date for product registration purposes. The responses given by the Agencies are based on the questions and documentation submitted for discussion and cannot account for future changes or developments in scientific knowledge or regulatory requirements. Scientific Advice given i
'/>"/>

SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Pa. , July 1, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... that Bob Radie , president and chief ... conferences this summer. He will provide an update ... (ketorolac tromethamine) Nasal Spray, approved product ...
(Date:7/1/2015)... July 1, 2015 New exchange plan enrollees ... 2015 compared to the same time a year ago, ... (NASDAQ: ESRX ) Exchange Pulse™ report, released today. ... 2014, the number of new exchange plan enrollees who ... in the first quarter of 2015. However, when evaluating ...
(Date:7/1/2015)... The Haselmeier Group has decided ... Gert Weber has been nominated by the Board ... Executive Officer (CEO) of the Haselmeier Group. This ... Mr. Weber brings more than 20 years of experience ... various executive management positions, the last being Managing Director ...
Breaking Medicine Technology:Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 2Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 4Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2
... 14 ERT (Nasdaq: ERES ) announced today that it will ... 2010 , after the market closes. After the release, the Company will host ... , , ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when ...
... PALO ALTO, Calif. , July 14 ... developed a medical device and procedure to treat vaginal ... accepted for the 2010 International Meetings for the International ... as a joint meeting in 2010, and the International ...
Cached Medicine Technology:ERT to Announce Second Quarter 2010 Results on August 9, 2010 2Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences 2Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences 3
(Date:7/1/2015)... ... July 01, 2015 , ... Did you know that infertility in men is ... we at Advanced Fertility Center of Texas (AFCT) would like to talk about some ... is often considered to be a “woman’s issue,” male fertility factors can play a ...
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will partner ... Twin Cities on Saturday, August 1, at Spring Lake Park High School. , During ... than $1 million worth of goods and services including free food, health services, family ...
(Date:7/1/2015)... ... July 01, 2015 , ... Scoliosis is a disorder in which the normally straight ... it affects 2 to 3 percent of the population, or an estimated 6 to 9 ... in children between the ages of 10 and 15. Most types of scoliosis are more ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... mesothelioma compensation law has just published a top ten list they hope will ... report. Click here to read it now. , More than ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, the only full-service leadership solutions ... chief nursing officer recruitment for Capital Health in Pennington, N.J. One ... Smith has recently placed more than 1,000 healthcare executives into organizations. , Capital ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... arthritic symptoms so severe that some victims can,t even walk. ... last up to a year., More than two million people ... Most of the infections have occurred in Southeast Asia, but ... likely because of global travel., With no vaccine available for ...
... Goodwin HealthDay Reporter , WEDNESDAY, April 27 (HealthDay News) ... U.S. population -- live in areas where the air is so ... says. Residents of Honolulu and Santa Fe-Espanola, N.M., on the ... is among the country,s cleanest -- and they were the only ...
... An experimental new drug that may treat hepatitis C more ... panel of experts for the U.S. Food and Drug Administration. ... be prescribed in combination with two existing drugs to help ... damage, according to documents posted by the FDA on its ...
... Serena Gordon HealthDay Reporter , TUESDAY, April 26 ... leaves the house, Nancy Geller worries about the food her ... allergy, and exposure to even a small amount of a ... "It,s a big worry, especially now that she,s a teenager ...
... cycles, known as circadian rhythms, are important for proper ... health. Disruptions of circadian rhythms and sleep-wake cycles have ... study by Douglas Institute researchers unravels a possible basis ... of clock genes in multiple areas of the human ...
... the context of rising levels of cardiovascular disease (CVD) in ... announces that for the first time- the Society will send ... of Cardiology (APCC). The 18th edition of the APCC ... to 8 May 2011. The ESC deputation will present an ...
Cached Medicine News:Health News:University of Houston wins NIH grant for vaccine study 2Health News:University of Houston wins NIH grant for vaccine study 3Health News:Report: California Cities Have Worst Air Pollution in U.S. 2Health News:Report: California Cities Have Worst Air Pollution in U.S. 3Health News:Report: California Cities Have Worst Air Pollution in U.S. 4Health News:Novel Hepatitis C Drug Holds Promise: FDA 2Health News:Anxiety's on the Menu for People With Food Allergies 2Health News:Anxiety's on the Menu for People With Food Allergies 3Health News:Researchers observe disruptions of daily rhythms in Alzheimer's patients' brains 2Health News:The European Society of Cardiology organizes educational program in Asia 2
... Simplex™ P with Tobramycin ... Bone Cement formula, with the ... By maintaining the original formula, ... performance characteristics of Simplex™ P ...
... Flow Analyzer is a fast, clinically proven ... of low and normal-tension glaucoma., ,The Ocular ... clinically proven measurement that improves detection of ... management of glaucoma, and detection of other ...
... Flexible Dosposable Easy Insertion/Removal ... (CSS) provides absolutely reliable support to ... thereby permitting routine phacoemulsification regardless of ... easy (similar to disposable iris retractors), ...
The collagen intracanicular plugs have a smooth proprietary finish that simplifies insertion of the plug. Collagen plugs are ideal for short term, diagnostic and post-surgical occlusion. Plugs are 2m...
Medicine Products: